As mentioned above, two clinical trials, CheckMate-648 and NCT01938612, have confirmed the efficacy and safety of combined CTLA-4 and PD-1 inhibitors as the immunotherapy of ESCC (176, 184). Here, CTLA4 is linked to esophageal squamous cell carcinoma.